EP2285217A4 - Composés utilisables pour l'amélioration de l'apprentissage et de la mémoire - Google Patents
Composés utilisables pour l'amélioration de l'apprentissage et de la mémoireInfo
- Publication number
- EP2285217A4 EP2285217A4 EP09747284A EP09747284A EP2285217A4 EP 2285217 A4 EP2285217 A4 EP 2285217A4 EP 09747284 A EP09747284 A EP 09747284A EP 09747284 A EP09747284 A EP 09747284A EP 2285217 A4 EP2285217 A4 EP 2285217A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- memory
- improving learning
- learning
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5260008P | 2008-05-12 | 2008-05-12 | |
PCT/US2009/043467 WO2009140200A1 (fr) | 2008-05-12 | 2009-05-11 | Composés utilisables pour l'amélioration de l'apprentissage et de la mémoire |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2285217A1 EP2285217A1 (fr) | 2011-02-23 |
EP2285217A4 true EP2285217A4 (fr) | 2011-06-08 |
Family
ID=41319017
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09747284A Withdrawn EP2285217A4 (fr) | 2008-05-12 | 2009-05-11 | Composés utilisables pour l'amélioration de l'apprentissage et de la mémoire |
EP09763136A Withdrawn EP2296472A4 (fr) | 2008-05-12 | 2009-05-11 | Composés pour inhiber les rho kinases et pour améliorer l'apprentissage et la mémoire |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09763136A Withdrawn EP2296472A4 (fr) | 2008-05-12 | 2009-05-11 | Composés pour inhiber les rho kinases et pour améliorer l'apprentissage et la mémoire |
Country Status (10)
Country | Link |
---|---|
US (3) | US20110294789A1 (fr) |
EP (2) | EP2285217A4 (fr) |
JP (2) | JP2011519972A (fr) |
KR (2) | KR20110011669A (fr) |
CN (2) | CN102088853A (fr) |
AU (2) | AU2009246568A1 (fr) |
BR (2) | BRPI0912337A2 (fr) |
CA (2) | CA2725416A1 (fr) |
MX (2) | MX2010012103A (fr) |
WO (2) | WO2009140200A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0912337A2 (pt) * | 2008-05-12 | 2019-09-24 | Amnestix Inc | composto método para melhorar memória em paciente, e, método para tratar condições |
US8703736B2 (en) * | 2011-04-04 | 2014-04-22 | The Translational Genomics Research Institute | Therapeutic target for pancreatic cancer cells |
AU2013207972B2 (en) * | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
AR094664A1 (es) | 2013-01-15 | 2015-08-19 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
BR112015021524A2 (pt) * | 2013-03-04 | 2017-07-18 | Advanced Medical Res Institute Of Canada | derivados de sulfonil quinolina e usos dos mesmos |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9617214B2 (en) | 2013-11-08 | 2017-04-11 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
WO2016010897A1 (fr) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016196244A1 (fr) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
NZ742476A (en) | 2015-12-17 | 2022-09-30 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
WO2019015608A1 (fr) * | 2017-07-19 | 2019-01-24 | 南京明德新药研发股份有限公司 | Dérivé d'isoquinoléinylsulfonyle et son utilisation |
WO2019113487A1 (fr) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs |
EP3868408A4 (fr) | 2018-10-15 | 2022-07-06 | National University Corporation Tokai National Higher Education and Research System | Antipsychotique et utilisation associée |
JP2023509970A (ja) | 2020-01-09 | 2023-03-10 | ウールジー・ファーマシューティカルズ・インコーポレイテッド | 皮質性認知症に関連する徘徊を治療する方法 |
CA3169944A1 (fr) * | 2020-03-25 | 2021-09-30 | Thomas Macallister | Methodes d'utilisation d'inhibiteurs de la kinase associee a rho pour traiter la demence fronto-temporale |
JP2023518707A (ja) | 2020-03-25 | 2023-05-08 | ウールジー・ファーマシューティカルズ・インコーポレイテッド | タンパク質症に関連する徘徊を治療する方法 |
CN115996728A (zh) * | 2020-04-23 | 2023-04-21 | 乌尔塞制药公司 | 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 |
MX2022015800A (es) * | 2020-06-15 | 2023-01-24 | Woolsey Pharmaceuticals Inc | Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. |
MX2022016336A (es) * | 2020-06-25 | 2023-01-24 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de trastornos del neurodesarrollo. |
EP4181925A1 (fr) * | 2020-07-14 | 2023-05-24 | Woolsey Pharmaceuticals, Inc. | Méthodes de traitement de protéinopathies |
US11311553B1 (en) | 2020-10-22 | 2022-04-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106325A1 (fr) * | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Promedicaments de 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine |
WO2008019395A2 (fr) * | 2006-08-10 | 2008-02-14 | Translational Genomics Research Institute | Composés pour améliorer l'apprentissage et la mémoire |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
CN100389828C (zh) * | 1996-08-12 | 2008-05-28 | 三菱制药株式会社 | 含Rho激酶抑制剂的药物制剂 |
AU4990599A (en) * | 1998-07-14 | 2000-02-07 | Brigham And Women's Hospital | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
US7115607B2 (en) * | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
AU2003228348A1 (en) * | 2002-03-20 | 2003-10-08 | John T. Fassett | Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors |
ES2361924T3 (es) * | 2002-12-20 | 2011-06-24 | X-Ceptor Therapeutics, Inc. | Derivados de isoquinolinona y su uso como agentes terapéuticos. |
US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
WO2005117896A1 (fr) * | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulations contenant du fasudil, une matrice et une enveloppe |
BRPI0614974A2 (pt) * | 2005-08-30 | 2010-12-14 | Asahi Kasei Pharma Corp | composto, medicamento, inibidor da fosforilaÇço da cadeia leve regulatària da miosina, inibidor da via rho/rho quinase, e, mÉtodo para tratamento terapÊutico e/ou profilÁtico de glaucoma |
KR20080063806A (ko) * | 2005-10-06 | 2008-07-07 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 피라졸로피리미딘 |
BRPI0912337A2 (pt) * | 2008-05-12 | 2019-09-24 | Amnestix Inc | composto método para melhorar memória em paciente, e, método para tratar condições |
-
2009
- 2009-05-11 BR BRPI0912337A patent/BRPI0912337A2/pt not_active IP Right Cessation
- 2009-05-11 CA CA2725416A patent/CA2725416A1/fr not_active Abandoned
- 2009-05-11 JP JP2011509589A patent/JP2011519972A/ja active Pending
- 2009-05-11 CN CN2009801280346A patent/CN102088853A/zh active Pending
- 2009-05-11 MX MX2010012103A patent/MX2010012103A/es unknown
- 2009-05-11 CA CA2723472A patent/CA2723472A1/fr not_active Abandoned
- 2009-05-11 EP EP09747284A patent/EP2285217A4/fr not_active Withdrawn
- 2009-05-11 BR BRPI0912386A patent/BRPI0912386A2/pt not_active IP Right Cessation
- 2009-05-11 EP EP09763136A patent/EP2296472A4/fr not_active Withdrawn
- 2009-05-11 AU AU2009246568A patent/AU2009246568A1/en not_active Abandoned
- 2009-05-11 WO PCT/US2009/043467 patent/WO2009140200A1/fr active Application Filing
- 2009-05-11 MX MX2010012104A patent/MX2010012104A/es unknown
- 2009-05-11 CN CN2009801280331A patent/CN102316737A/zh active Pending
- 2009-05-11 AU AU2009257926A patent/AU2009257926A1/en not_active Abandoned
- 2009-05-11 WO PCT/US2009/043464 patent/WO2009151845A1/fr active Application Filing
- 2009-05-11 KR KR1020107027640A patent/KR20110011669A/ko not_active Application Discontinuation
- 2009-05-11 US US12/991,846 patent/US20110294789A1/en not_active Abandoned
- 2009-05-11 KR KR1020107027499A patent/KR20110014183A/ko not_active Application Discontinuation
- 2009-05-11 JP JP2011509590A patent/JP2011519973A/ja active Pending
- 2009-05-11 US US12/991,839 patent/US20110237600A1/en not_active Abandoned
- 2009-11-11 US US12/616,581 patent/US20100160297A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106325A1 (fr) * | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Promedicaments de 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine |
WO2008019395A2 (fr) * | 2006-08-10 | 2008-02-14 | Translational Genomics Research Institute | Composés pour améliorer l'apprentissage et la mémoire |
Non-Patent Citations (1)
Title |
---|
See also references of WO2009140200A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR20110011669A (ko) | 2011-02-08 |
US20100160297A1 (en) | 2010-06-24 |
MX2010012103A (es) | 2011-04-04 |
US20110237600A1 (en) | 2011-09-29 |
EP2296472A4 (fr) | 2011-06-08 |
JP2011519972A (ja) | 2011-07-14 |
CN102316737A (zh) | 2012-01-11 |
WO2009151845A1 (fr) | 2009-12-17 |
CN102088853A (zh) | 2011-06-08 |
MX2010012104A (es) | 2011-04-05 |
AU2009257926A1 (en) | 2009-12-17 |
JP2011519973A (ja) | 2011-07-14 |
WO2009140200A1 (fr) | 2009-11-19 |
WO2009151845A9 (fr) | 2010-01-28 |
EP2285217A1 (fr) | 2011-02-23 |
KR20110014183A (ko) | 2011-02-10 |
EP2296472A1 (fr) | 2011-03-23 |
US20110294789A1 (en) | 2011-12-01 |
AU2009246568A1 (en) | 2009-11-19 |
CA2723472A1 (fr) | 2009-12-17 |
BRPI0912386A2 (pt) | 2016-07-26 |
BRPI0912337A2 (pt) | 2019-09-24 |
CA2725416A1 (fr) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2285217A4 (fr) | Composés utilisables pour l'amélioration de l'apprentissage et de la mémoire | |
GB2459107B (en) | Access point | |
EP2240343A4 (fr) | Disque à mémoire de forme | |
GB0821482D0 (en) | Access control | |
EP2061314A4 (fr) | Composés pour améliorer l'apprentissage et la mémoire | |
ZA201104301B (en) | Access device | |
HK1145677A1 (en) | Substituted piperidino dihydrothienopyrimidines | |
EP2115594A4 (fr) | Systeme de memoire | |
EP2250564A4 (fr) | Système de mémoire | |
EP2250567A4 (fr) | Système de mémoire | |
EP2269139A4 (fr) | Système de mémoire | |
EP2250565A4 (fr) | Système de mémoire | |
EP2248024A4 (fr) | Système de mémoire | |
EP2248027A4 (fr) | Système de mémoires | |
EP2260391A4 (fr) | Système de mémoire | |
EP2250566A4 (fr) | Système de mémoire | |
EP2260390A4 (fr) | Système de mémoire | |
EP2248022A4 (fr) | Systeme de memoires | |
EP2248026A4 (fr) | Systeme de memoires | |
IL206929A0 (en) | Dilator | |
AU324981S (en) | Closure | |
EP2271988A4 (fr) | Système de mémoire | |
EP2118756A4 (fr) | Système de mémoire | |
GB2458118B8 (en) | Access control | |
EG25875A (en) | Drinks-can-lid closure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110511 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20110505BHEP Ipc: A61K 31/497 20060101ALI20110505BHEP Ipc: A61K 31/47 20060101ALI20110505BHEP Ipc: A01N 43/42 20060101AFI20091203BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111210 |